Lebrikizumab

Summary

Lebrikizumab (CHEMBL1743035) is an approved antibody (ATC D11AH10); indicated across 6 conditions including atopic eczema and asthma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: D11AH10
• Indications: 6 conditions
• Clinical trials: 45

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743035
Name	Lebrikizumab
Type	Antibody
Max phase	4
ATC	D11AH10

Also known as: Ebglyss, Lebrikizumab, Lebrikizumab-lbkz, MILR-1444A, MILR1444A, PRO-301444, PRO-301444 RG-3637, PRO301444, RO-5490255, Tnx-650, LEBRIKIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atopic eczema	4	MONDO:0004980	EFO:0000274
asthma	3	MONDO:0004979	MONDO:0004979
chronic obstructive pulmonary disease	2	MONDO:0005002	EFO:0000341
idiopathic pulmonary fibrosis	2	MONDO:0800504	EFO:0000768
Hodgkins lymphoma	1	MONDO:0004952	EFO:0000183

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 45.

Phase distribution

Phase	Trials
PHASE3	23
PHASE2	12
PHASE1	5
PHASE4	3
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06906497	PHASE4	RECRUITING	Lebrikizumab in Moderate-to-severe Atopic Dermatitis
NCT07006792	PHASE4	ACTIVE_NOT_RECRUITING	A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT05559359	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483	PHASE3	ENROLLING_BY_INVITATION	A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05990725	PHASE3	ACTIVE_NOT_RECRUITING	Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
NCT06280716	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
NCT06526182	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
NCT06921759	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
NCT07542483	PHASE3	NOT_YET_RECRUITING	A Study of Lebrikizumab in Adults With Nummular Eczema
NCT01867125	PHASE3	COMPLETED	A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
NCT01868061	PHASE3	COMPLETED	A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication
NCT01875003	PHASE3	COMPLETED	A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
NCT02104674	PHASE3	COMPLETED	A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
NCT02546869	PHASE3	WITHDRAWN	A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting
NCT04146363	PHASE3	COMPLETED	Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
NCT04178967	PHASE3	COMPLETED	Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
NCT04250337	PHASE3	COMPLETED	Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
NCT04250350	PHASE3	COMPLETED	Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
NCT04392154	PHASE3	COMPLETED	Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
NCT04626297	PHASE3	COMPLETED	A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
NCT04760314	PHASE3	COMPLETED	A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
NCT05149313	PHASE3	COMPLETED	A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
NCT05369403	PHASE3	COMPLETED	A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
NCT05372419	PHASE3	COMPLETED	A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
NCT05916365	PHASE3	COMPLETED	Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
NCT00441818	PHASE1/PHASE2	UNKNOWN	Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin’s Lymphoma
NCT00781443	PHASE2	COMPLETED	A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
NCT00930163	PHASE2	COMPLETED	A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids
NCT00971035	PHASE2	COMPLETED	A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids
NCT01545440	PHASE2	COMPLETED	A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)
NCT01545453	PHASE2	COMPLETED	A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)
NCT01872689	PHASE2	COMPLETED	A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT01987492	PHASE2	COMPLETED	A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
NCT02099656	PHASE2	COMPLETED	A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma
NCT02340234	PHASE2	COMPLETED	A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
NCT02465606	PHASE2	COMPLETED	A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
NCT02546700	PHASE2	COMPLETED	A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT03443024	PHASE2	COMPLETED	A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
NCT07471932	PHASE1	RECRUITING	A Study of LAD106 in Healthy Adult Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).